2013 ASH®State-of-the-Art Symposium
The 2013 State-of-the-Art Symposium (SAS) took place on September 28-29 in Chicago, IL, and on October 11-12 in Los Angeles, CA.
Both SAS meetings featured leading hematology experts who discussed recent advances in hematologic malignancies, with a special focus on myelodysplastic syndromes.
Roy L. Silverstein, MD
Medical College of Wisconsin
Blood Center of Wisconsin
David P. Steensma, MD
Harvard Medical School
Dana-Farber Cancer Institute
2013 Program Topics
- VTE: Risk Assessment and Extended Anticoagulation
- Heparin-Induced Thrombocytopenia: Novel Insights in Pathobiology, Diagnosis, and Treatment
- An Embarrassment of Riches: Choosing a Kinase Inhibitor for the Patient with CML
- Myeloproliferative Neoplasms: Where Do We Go From Here?
- BTK Inhibitors, PI3K Inhibitors, Etc.- Novel Therapies for CLL
- The Next Generation of Antibodies and Antibody Conjugates in Lymphoma
- Molecular Testing in the Evaluation of Patients with MDS or Idiopathic Cytopenias
- What are the Options When Hypomethylating Agent Fails the Patient with MDS?
- New Insights into the Sideroblastic Anemias
- New Therapies for Multiple Myeloma
- von Willebrand Disease: Challenging Diagnostic and Therapeutic Issues
- CART19 Cellular Therapy for B-Cell Leukemias
back to top
2012 ASH®State-of-the-Art Symposium
The 2012 State-of-the-Art Symposium (SAS) took place on September 28-29 in Chicago, IL, and on October 12-13 in Los Angeles, CA.
Both SAS meetings featured leading hematology experts who discussed recent advances in hematologic malignancies, with a special focus on thrombosis.
Nancy Bartlett, MD
Thomas Ortel, MD, PhD
2012 Program Topics
- Thrombopoietic Agents for Idiopathic Thrombocytopenia
- American College of Chest Physicians (ACCP) Antithrombotic Guidelines with a Focus on Perioperative Management of Anticoagulant Therapy
- Thrombosis in Cancer - Review of Current ASCO and NCCN Treatment Guidelines
- Myelodysplastic Syndromes - The Role of Stem Cell Transplant in the Era of Hypomethylating Agents
- Myeloid Leukemia - Management of Older Patients
- Diffuse Large B-Cell Lymphoma - Should Cell of Origin and Molecular Characteristics Guide Therapy?
- Central Nervous System Lymphoma - Treatment and Prevention
- Follicular Lymphoma - Who, When, and How to Treat?
- Mantle Cell Lymphoma (MCL) - Where Do New Agents Fit in the Management of MCL?
- T-Cell Lymphoma - Current Approaches and New Agents
- Hodgkin Lymphoma - Out with the Old (Radiation Therapy), In with the New (Brentuximab Vedotin)
- Chronic Lymphocytic Leukemia (CLL) - Frontline and Salvage Therapy for High Risk CLL
back to top